2-DG Inhibits SARS-COV-2 Growth and Cyto-Pathic Effect:
- The first batch of the indigenously developed anti-Covid drug, 2-Deoxy-D-Glucose oral powder or ‘2-DG’ released by Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday (May 17).
- Developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in association with Hyderabad-based Dr Reddy’s Laboratories (DRL)
- Drugs Controller General of India (DCGI) cleared the formulation on May 1 for emergency use to be used together with the primary treatment in both moderate and severe Covid-19 patients
To buy our online courses: Click Here
- Clinical trials show that the molecule helps in faster recovery of patients hospitalised with Covid-19 and reduces their dependence on auxiliary oxygen
- Patients improved symptomatically and become free from supplemental oxygen dependence by 42% on the 3rd day when compared to 31% using traditional SoC.
- A 2.5 days difference in median time to achieve normalisation of specific vital sign parameters when compared to SoC.
- Phase 2 trials conducted on 110 patients between May and October 2020
- Phase 2A was conducted in six hospitals,
- Phase 2B involved dose-ranging (clinical trial using different doses) was conducted in 11 hospitals across the country
- Phase 3 clinical trials in November 2020
- Final trials were carried out on 220 patients admitted to 27 Covid hospitals in various districts between December 2020 and March 2021
How it works
- 2-DG drug spreads through the body just like glucose. The virus needs glucose for energy. Replica of glucose/ glucose analogue forces the virus to think it is glucose.
- It reaches the virus-infected cells and prevents virus growth by stopping viral synthesis. Glycolysis, the breakdown of glucose to extract energy for cellular metabolism stops and so does energy production.
- It gets inside the virus-cell and cuts off the glucose required for the virus to grow. The virus stops multiplying automatically. Helps in reducing the infection and the viral load gradually
- Its selective accumulation in virally infected cells makes this drug unique
- 10000 doses expected to be released for trial
- The anti-COVID drug 2-DG has been developed in powder form and is ingested orally by dissolving it in water
- A patient may have to take this drug twice a day for about five to seven days.
Availability and price
- 2-DG being a generic molecule and an analogue of glucose, it can be easily produced and made available in large quantities
- Supply to major hospitals to begin by mid-June
- It will be low-cost and will be priced inexpensively
(2-DG Inhibits SARS-COV-2 Growth and Cyto-Pathic Effect)
Also Read: New Shrew like mammal discovered